#Aerie Pharmaceuticals (AERI)

Exelixis and Aerie Have Good News

Exelixis & Aerie Have Good News Exelixis' Good News about Cabometyx Takeda Pharmaceuticals applied to the Japanese Ministry of Health, Labor and Welfare (MHLW) for approval to manufacture and to s...

P

Prohost Biotech

Apr 25, 2019

8m

1

News & Comments

Aerie’s successful new confirmatory study for Rhopressa® was a necessity

Aerie Pharmaceuticals (AERI) announced results from a double-masked, randomized, placebo-controlled study designed to evaluate the effect of its glaucoma product Rhopressa® (netarsudil ophthalmic solu...

P

Prohost Biotech

Aug 15, 2018

The Year in Review Part 1

Prohost Letter #416 Part 1 The Year In Review - 2017 Unheard of Programs - AN AWESOME YEAR for the biotech sector regarding its accomplishments. Many of the accomplished programs were unheard of regar...

P

Prohost Biotech

Dec 31, 2017

1m

11

News & Comments

The FDA Approved Aerie Pharmaceuticals’ Glaucoma Eye Drops Rhopressa. What’s Next?

Two months ahead of the PDUFA date scheduled for February 28, 2018, the Food and Drug Administration (FDA) approved Aerie Pharmaceuticals’ (AERI) ophthalmic solution) 0.02% Rhopressa® (netarsudil for...

P

Prohost Biotech

Dec 22, 2017

Prohost Letter #414

Prohost Letter #414 GIANTS & DWARFS - We believe it’s a useful idea bringing The Week in Review into the Prohost Letter this time. We thought it would be easier for the readers to get last week’s upda...

P

Prohost Biotech

Oct 25, 2017

Confirmed as Therapeutic Molecules, Alnylam’s RNAI Made the Most Important News of the Week and the Year

The Week in Review #5 ALNYLAM (ALNY) a nd Sanofi Genzyme , the specialty care global business unit of Sanofi announced that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic f...

P

Prohost Biotech

Sep 25, 2017

Calming Down PTC Therapeutics Investors' Concerns. More Good News from Sangamo. AERIE's Glaucoma Drug NDA

PTC THERAPEUTICS Why Buying Emflaza? Buying Emflaza, a steroid approved by the FDA for Duchenne muscular dystrophy (DMD) from Marathon Pharmaceuticals invited an intractable headache to PTC Pharmaceut...

P

Prohost Biotech

May 18, 2017

Prohost Letter #400

Prohost Letter #400 NEAR-TERM INVESTING Th e Pro h os t L e tt e r # 39 9 Pa r t 3 ha s P ro m i se d t o D es c ri b e t ...

P

Prohost Biotech

Oct 27, 2016

1m

2

News & Comments

Why Aerie Pharmaceuticals' Stock Rallied Today. What About Now?

As we expected in our previous articles, Today, Aerie Pharmaceuticals (AERI) came up with great news about its glaucoma treatment. The stock surged …. On February 18, 2016, Under News & Comment...

P

Prohost Biotech

Sep 15, 2016

Amgen: Positive Data from Osteoporosis Trial. Aerie Pharmaceuticals: More Data on Glaucoma Drug Safety.

Amgen (AMGN) and UCB (Euronext Brussels: UCB) announced positive results from the BRIDGE pivotal Phase 3 placebo-controlled study evaluating the efficacy and safety of romosozumab in treating men wit...

P

Prohost Biotech

Mar 22, 2016

1m

3

News & Comments

AERIE Pharmaceuticals: The Novel Glaucoma Eye Drops Confirm Their Superiority

On February 4, 2015, we wrote an article titled, “Aerie Pharmaceuticals is speeding towards improving the treatment of glaucoma”, posted under News & Comments at the Prohost website, we wrote the...

P

Prohost Biotech

Feb 18, 2016

10m

4

News & Comments

Aerie Pharmaceuticals: Another Step Forward Towards the Approval of a Promising Glaucoma Drug

Aerie Pharmaceuticals (AERI), which is specialized in glaucoma treatments reported successful results of its second Phase 3 trial for Rhopressa™ — a novel once-daily, triple-action eye drops for glauc...

P

Prohost Biotech

Sep 17, 2015

8m

3

News & Comments

Aerie Pharmaceuticals Is Speeding Towards Improving the Magement of Glaucoma

AERIE PHARMACEUTICALS (AERI) A YOUNG BUT STRONG COMPETITOR IN THE GLAUCOMA HUGE MARKET - Aerie Pharmaceuticals has eye drops that could become a game changer in the management of glaucoma. - The fir...

P

Prohost Biotech

Feb 11, 2015

8m

3